BETHESDA, Md.--(BUSINESS WIRE)--July 3, 2006--RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN - News; www.regenerx.com) reported today that Mexico has issued a notice of allowance for the patent application: Thymosin beta 4 (TB4) promotes wound repair. The original patent application filed by the National Institutes of Health and licensed to RegeneRx, claims numerous compositions, uses and processes related to TB4 and wound healing. Similar applications have been filed in other territories throughout the world, including in the U.S. and Asia, several of which have previously been granted. RegeneRx has independently filed over fifty additional world-wide patent applications related to its technology platform.
